Relapse-free survival of 96 patients with high-grade malignant B-cell lymphomas having achieved complete response by the COP-BLAM/IMVP-16 regimen (BMFT trial5 ); (patients at risk at 1/2/3/4 years). Lymphoma entities (Kiel classification): ———, centroblastic n = 72 (53/40/25/6); - - - -, B-anaplastic large cell (CD30⁺) n = 10 (7/5/3/3); ⋅⋅⋅⋅, B-immunoblastic n = 14 (4/3/3/2) P = .0025.